| 熊林楷,黄小华,杨根辉,肖辉,徐炎良,陈颖兰.非小细胞肺癌患者表皮生长因子受体基因突变的危险因素分析*[J].实用中西医结合临床,2020,20(10): |
| 非小细胞肺癌患者表皮生长因子受体基因突变的危险因素分析* |
| 非小细胞肺癌患者表皮生长因子受体基因突变的危险因素分析* |
| 投稿时间：2020-07-01 修订日期：2020-07-01 |
| DOI： |
| 中文关键词: 非小细胞肺癌 表皮生长因子受体 危险因素 |
| 英文关键词: |
| 基金项目: |
|
| 摘要点击次数: 521 |
| 全文下载次数: 221 |
| 中文摘要: |
| 目的 探讨非小细胞肺癌(NSCLC)患者表皮生长因子受体(EGFR)基因突变的危险因素。 方法 选取2019年1月-2020年3月江西省肿瘤医院收治的111例NSCLC患者作为研究对象,根据EGFR突变结果将其分为突变组(76例)与非突变组(35例)。采用单因素分析法、多因素Logistic回归分析法对研究对象临床资料指标进行分析。 结果 突变组与非突变组性别、年龄、病理组织学分类、M分期、吸烟史比较差异有统计学意义(P＜0.05),T分期、N分期、并发脑转移、并发骨转移、并发其他脏器转移、ECOG PS评分,血清CEA、CyFra 21-1、CA15-3、SCCA比较差异无统计学意义(P＞0.05)。多因素Logistic回归分析显示,女性、腺癌、M1期、无吸烟史是NSCLC患者EGFR突变的独立危险因素(P＜0.05),年龄是NSCLC患者EGFR突变的非独立相关因素(P＞0.05)。 结论 临床应加强女性、腺癌、M1期、无吸烟史NSCLC患者的EGFR突变检测,并根据检测结果指导治疗。 |
| 英文摘要: |
| Objective To analyze the risk factors related to epidermal growth factor receptor(EGFR) gene mutation in patients with non-small cell lung cancer(NSCLC). Methods 111 cases of NSCLC admitted into Jiangxi cancer hospital from January 2019 to March 2020 were selected as the study objects. According to the mutation results of EGFR, they were divided into mutation group (76 cases) and non-mutation group (35 cases). The single-factor analysis and multi-factor Logistic regression analysis were used to analyze the clinical data of all subjects. Results There were significant differences in gender, age, histopathological classification, M stage and smoking history between mutation group and non-mutation group (P<0.05),while no significant differences were found in T stage, N stage, brain metastasis, bone metastasis, other organ metastasis, ECOG PS scores and serum CEA, CyFra 21-1, CA15-3, SCCA between the 2 groups (P>0.05). The multi-factor Logistic regression analysis showed that women, adenocarcinoma, M1 stage and no-smoking history were independent risk factors for EGFR mutation in NSCLC patients (P<0.05), while age was a independent factor (P>0.05). Conclusion We should strengthen the detection of EGFR mutation in female, adenocarcinoma, M1 stage and no-smoking history NSCLC patients, then guide the treatment according to the EGFR mutation results. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
